View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNuvalent 향후 성장Future 기준 점검 2/6Nuvalent은 연간 수입과 매출이 각각 60.3%와 58.1% 증가할 것으로 예상되고 EPS는 연간 60.7%만큼 증가할 것으로 예상됩니다.핵심 정보60.3%이익 성장률60.65%EPS 성장률Biotechs 이익 성장23.9%매출 성장률58.1%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트16 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.공고 • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.공고 • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.이익 및 매출 성장 예측DB:5AX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028506-106-211-35712/31/2027168-357-461-266812/31/202610-449-357-33283/31/2026N/A-450-313-313N/A12/31/2025N/A-425-275-275N/A9/30/2025N/A-381-264-264N/A6/30/2025N/A-343-239-239N/A3/31/2025N/A-301-204-204N/A12/31/2024N/A-261-185-185N/A9/30/2024N/A-224-153-153N/A6/30/2024N/A-174-130-130N/A3/31/2024N/A-146-111-111N/A12/31/2023N/A-126-100-100N/A9/30/2023N/A-114-87-87N/A6/30/2023N/A-100-83-83N/A3/31/2023N/A-89-76-76N/A12/31/2022N/A-82-65-65N/A9/30/2022N/A-73-60-60N/A6/30/2022N/A-66-53-53N/A3/31/2022N/A-57-48-48N/A12/31/2021N/A-46-40-40N/A9/30/2021N/A-36-32-32N/A6/30/2021N/A-28-25-25N/A3/31/2021N/A-27-18-18N/A12/31/2020N/A-15-15-15N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 5AX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 5AX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 5AX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 5AX 의 수익(연간 58.1%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 5AX 의 수익(연간 58.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 5AX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 07:39종가2026/07/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nuvalent, Inc.는 24명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Colleen KusyBairdEtzer DaroutBarclaysJeffrey WalchBernstein21명의 분석가 더 보기
공고 • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.
공고 • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.
공고 • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.